Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Sep
17
Today In Oncology
FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Zipalertinib Added to Chemotherapy Improves PFS in First-Line EGFR Exon 20 NSCLC
FDA Approves New Labeling of ROS1 Inhibitor for NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo